Latest filingSep 03, 2026Most recent Form 4
REGN
REGENERON PHARMACEUTICALS, INC.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$234M3 sells
Net open-market-$234M4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period11transactions
- M · Option exercise · dominant6 · 55%
- S · Open-market sells3 · 27%
- F · Tax withholding2 · 18%
Activity by reported role
A joint filing can contribute to multiple roles11transactions
- Director · dominant3 · 27%
- EFC3 · 27%
- GC3 · 27%
- EC2 · 18%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeFenimore Christopher R.Common Stock · Direct
19,984Aug 18, 2026
Larosa Joseph JCommon Stock · Direct
45,392Aug 19, 2026
Guarini KathrynCommon Stock · Direct
603Sep 02, 2026
McCourt MarionCommon Stock · Direct
12,003Sep 03, 2026
Fenimore Christopher R.Non-Qualified Stock Option (right to buy) · Direct
6,000Aug 18, 2026
Larosa Joseph JNon-Qualified Stock Option (right to buy) · Direct
12,283Aug 19, 2026
Guarini KathrynNon-Qualified Stock Option (right to buy) · Direct
1,158Sep 02, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- MM-$2.0M
- GK-$340.0k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
REGN transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| REGN | McCourt Marion | EC | sale10b5-1 | 1.13k | -$96.9M | S | — | 0.0% | 09/03 | 09/03 |
| REGN | McCourt Marion | EC | sale10b5-1 | 1.21k | -$103M | S | — | 0.0% | 09/03 | 09/02 |
| REGN | Guarini Kathryn | DIR | sale10b5-1 | 400 | -$34.0M | S | — | 0.0% | 09/03 | 09/02 |
REGENERON PHARMACEUTICALS, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at REGENERON PHARMACEUTICALS, INC.?
McCourt Marion, Guarini Kathryn, LAROSA JOSEPH J, Fenimore Christopher R..
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
McCourt Marion reported a sale on Sep 03, 2026 valued at $96.9M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $2,342,458.09. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.